Microvast Holdings announces departure of chief financial officer
On Monday, Truist Securities adjusted its stance on Iovance Biotherapeutics (NASDAQ:IOVA), shifting the rating from Buy to Hold. The stock, currently trading at $1.75, has experienced a significant decline of 50% in the past week alone. According to InvestingPro data, the broader analyst consensus remains bullish with price targets ranging from $10 to $30. The decision comes as the firm acknowledges the significant advancements Iovance has made with its TIL (tumor-infiltrating lymphocyte) therapy in treating melanoma. Despite the innovation, Truist Securities cites current market conditions and the company’s performance inconsistencies as reasons for the downgrade. The company maintains a strong liquidity position with a current ratio of 4.18 and more cash than debt on its balance sheet, though it’s currently burning through cash rapidly.
The statement from Truist Securities recognizes the pioneering efforts of Iovance in successfully bringing TIL therapy to the market, setting a new standard for melanoma treatment. However, the research firm has expressed concerns regarding Iovance’s ability to navigate the market effectively and deliver consistent results that meet or surpass expectations.
In light of these considerations, Truist Securities has revised its financial model for Iovance to factor in the company’s reduced guidance and heightened expenses. The analysts have pointed out that the anticipated market volatility, coupled with Iovance’s low stock price, has led them to eliminate their price target for the company’s shares.
This rating change reflects a cautious approach by Truist Securities towards Iovance Biotherapeutics as it grapples with the challenges of commercializing its TIL therapy and establishing a stable market presence. The firm’s decision underscores the importance of consistent performance and market adaptation for companies in the biotechnology sector. While the company has achieved remarkable revenue growth, InvestingPro analysis suggests the stock is currently undervalued, with 13 additional ProTips and a comprehensive Pro Research Report available for deeper insights into the company’s prospects.
In other recent news, Iovance Biotherapeutics reported a significant revenue miss in its first-quarter 2025 financial results, with earnings per share at -$0.36, falling short of the expected -$0.24. The company’s revenue reached $49.3 million, which was below the consensus estimate of $83.27 million. Following these results, Iovance adjusted its full-year 2025 revenue guidance to a range of $250 million to $300 million. The company attributed the revenue shortfall to reduced capacity during scheduled maintenance at its manufacturing facility, although production has now resumed.
Iovance’s financial position remains strong, with approximately $366 million in cash, expected to support operations into the second half of 2026. Analyst Colleen Kusy from Baird downgraded Iovance from Outperform to Neutral, citing the earnings miss and lowered sales guidance as key factors. Kusy also reduced the price target to $3.00 from $20.00, highlighting concerns over the company’s high cash burn rate. Meanwhile, H.C. Wainwright maintained a Buy rating on Iovance but reduced its price target to $20.00 from $32.00, reflecting ongoing optimism about the company’s long-term potential despite recent setbacks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.